SB950 —
-
1Introduced
-
2In Committee
-
3Passed Senate
-
4Passed House
-
5To Executive
-
6Enacted
This bill died with 2020 Regular Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
In plain language
The bill addresses the role of state-funded programs in drug pricing.
This bill focuses on how state-funded programs can influence drug pricing to ensure affordability. It emphasizes transparency and the need for clear communication regarding drug costs.
What this means for you
- Consumers: Consumers may see changes in drug pricing due to increased transparency from state-funded programs.
Sponsorship breakdown
Export CSV (upgrade) →0 sponsors · 0 co-sponsors · 77 not signed on
Sponsors (0)
None.
Co-sponsors (0)
None.
Not signed on (77)
77 members have not signed on to this bill.
Show all 77 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Frequently asked questions
- What is the current status of SB950?
- This bill died with 2020 Regular Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track SB950?
- Track SB950 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB950
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB950
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →